Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.
Company Details
- Employees
- 15
- Founded
- -
- Address
- San Francisco, Ca 94107, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://axi.om/
- HQ
- San Francisco, CA
Axiom Bio Questions
Axiom Bio's website is http://axi.om/
Axiom Bio's LinkedIn profile is https://www.linkedin.com/company/axiombio1
Axiom Bio has
15 employees.
View email and phone details for 15
employees at Axiom Bio.
Axiom Bio's industry is
Biotechnology Research
Axiom Bio's top competitors are
Astronomer,
Zetta Venture Partners,
Redesign Science,
Spring Science,
Axiome,
Genesis Therapeutics,
Stately Bio,
Freenome,
Axiom Therapeutics,
Dimension.
Axiom Bio's categories are Biotechnology Research
Axiom Bio's founding year is 2024
